🗞️ Why in News The 9th edition of India Pharma 2026 was inaugurated at Federation House, FICCI, New Delhi on April 13-14, 2026 by Union Minister Jagat Prakash (J.P.) Nadda (Chemicals & Fertilizers) and Minister of State Anupriya Patel. The theme — “Discover in India: Leapfrogging Life-Sciences Innovation” — signals a strategic shift from India’s “volume-driven generics” identity to value-led, IP-anchored pharmaceutical innovation.
India’s Pharma Sector at a Glance (2026)
| Metric | Value (2024-25 / 2025-26 est.) |
|---|---|
| Total domestic pharma market size | ~$55 billion |
| Exports | ~$27 billion (FY 2024-25) |
| Share of global generic supply (by volume) | ~20% (largest single-country source) |
| Share of world’s vaccine supply (by volume) | ~60% |
| Ranking | 3rd by volume (after USA, China); 11th by value globally |
| Number of FDA-approved facilities | >650 (highest outside USA) |
| R&D spend as % of revenue | ~7-8% (vs global Big Pharma at 15-18%) |
Why the volume-vs-value gap matters: India produces roughly one in every five generic pills consumed globally, but captures only about 3% of the global pharma industry’s value — because generics are low-margin commodities while innovator drugs (biologics, new molecular entities) command 10-30x pricing.
The Strategic Shift — From “Pharmacy” to “Discovery”
The Policy Framing
India Pharma 2026’s theme — “Discover in India” — echoes the government’s larger “Make in India” brand, now applied specifically to pharmaceutical R&D and intellectual property creation. The four identified shifts:
- Generics → Biosimilars + Complex Generics: Biosimilars (follow-on biologics of off-patent biologic drugs like Humira, Herceptin) and complex generics (inhalers, injectables, ophthalmics) are 3-5x more profitable than small-molecule generics
- Contract Manufacturing → CRDMO (Contract Research, Development & Manufacturing Organisation): Moving beyond “make it” to “design and make it” — capturing more of the value chain
- Small molecules → Biologics: mAbs (monoclonal antibodies), cell and gene therapies, mRNA platforms — all high-margin, IP-intensive
- Domestic + Export → Global IP Origination: Patents filed in India that get transferred globally, rather than licensing-in from Western innovators
Government Schemes Supporting the Shift
| Scheme | Outlay | Purpose |
|---|---|---|
| PLI for Pharmaceuticals (2021) | ₹15,000 crore | Incentives for manufacturing niche complex generics + drug intermediaries |
| PLI for Bulk Drugs / APIs (2020) | ₹6,940 crore | Reduce import dependence on Chinese APIs (from ~70% to target 30% by 2030) |
| Promotion of Bulk Drug Parks (2020) | ₹3,000 crore | 3 parks in Gujarat, Himachal Pradesh, Andhra Pradesh |
| PRIP — Promotion of Research & Innovation in Pharma MedTech (2023) | ₹5,000 crore | Support R&D in biosimilars, precision medicine, regenerative medicine |
| Strengthening of Pharmaceuticals Industry (SPI, 2022) | ₹500 crore | Common facility centres for MSME pharma |
The API (Active Pharmaceutical Ingredient) Paradox
India is the world’s largest supplier of finished formulations but imports roughly 70% of its APIs — the active chemical compounds that are the raw materials for drugs. Of those, approximately 68% come from China.
Why India’s API Self-Sufficiency Collapsed
- 1991-2000: India was largely self-sufficient in API production
- Post-2000: Chinese APIs flooded markets at 30-40% price discounts due to massive government subsidies, cheap energy, and environmental externalities
- Indian API manufacturers shuttered — ~70% of small API units closed between 2000-2015
- Result: India — the “Pharmacy of the World” — depends on China for its pharmacy’s raw materials
COVID-19 Wake-Up Call
During COVID-19 (2020), China’s temporary export restrictions on paracetamol APIs caused global shortages and price spikes. This triggered:
- PLI scheme for KSMs (Key Starting Materials) & APIs — ₹6,940 crore
- Bulk Drug Parks — to create clusters for backward integration
- Target: 50% API self-reliance by 2030
Biosimilars — India’s High-Value Opportunity
Biosimilars are follow-on versions of biologic drugs (monoclonal antibodies, insulin, EPO, G-CSF) once the original’s patent expires. Unlike small-molecule generics (simple chemical copies), biosimilars require new clinical trials because living cell-produced proteins cannot be replicated identically.
India’s Biosimilar Leadership
- India was the first country to approve a biosimilar globally — Reliance Life Sciences’ ReliGrast (filgrastim biosimilar) in 2007
- Indian firms (Biocon, Dr Reddy’s, Intas, Zydus, Lupin) lead the global biosimilar market by volume
- Indian biosimilars offer 50-70% price reductions versus originator biologics
Biosimilar Regulatory Pathway (India)
- CDSCO (Central Drugs Standard Control Organisation) approves biosimilars under 2016 guidelines
- DBT (Department of Biotechnology) co-regulates when live organisms are involved
- Reference Biologic must be approved in India or a regulated market (US/EU/Japan)
Global Biosimilar Market
- Projected $100+ billion by 2030 (from ~$35 billion in 2025)
- Major patent expiries (2026-2030): Humira (already), Stelara, Keytruda — each a $10-20 billion/year opportunity
- India’s share: Currently ~25-30% by volume globally; government target to capture 40%+ by 2030
The Innovation Ecosystem Gaps
Where India Lags
| Dimension | India | USA | China |
|---|---|---|---|
| NME (New Molecular Entity) approvals/year | 1-2 | 40-60 | 5-10 |
| Pharma R&D spend (USD) | ~$2 billion | ~$80 billion | ~$20 billion |
| Phase III trial cost (indicative) | $10-50 million | $50-200 million | $20-80 million |
| Patent filings (pharma, ~2024) | ~1,500 | ~15,000 | ~10,000 |
| Biotech IPOs (past 5 years) | <10 | ~500 | ~200 |
Structural Reasons for the Gap
- R&D funding gap — Indian pharma spends 7-8% on R&D; global innovators spend 15-18%. Reinvestment rates are structurally lower due to lower margins
- Risk capital shortage — Indian biotech VC ecosystem is ~15-20% the size of China’s, <5% of USA’s
- Regulatory friction — CDSCO-to-USFDA/EMA process harmonisation gaps slow multi-market trials
- Talent gap — Senior PhD-MD clinician-scientists (critical for translational research) still largely emigrate
- IP uncertainty — India’s Section 3(d) of the Patents Act, 1970 (disallowing ever-greening) creates periodic friction with originator firms — though this is also a public-health strength
Section 3(d) — India’s Compulsory Innovation Filter
Section 3(d) of the Patents Act, 1970 (inserted via the 2005 amendment) is central to India’s pharma landscape. It states that the “mere discovery of a new form of a known substance” is not patentable unless it shows enhanced efficacy.
The Novartis Case (2013)
Novartis AG v. Union of India — Supreme Court upheld Section 3(d) when Novartis tried to patent a new crystalline form of its cancer drug Gleevec (imatinib). The ruling’s impact:
- Positive: Prevents “ever-greening” — extending patents through minor molecular modifications; keeps generics affordable
- Negative: Big Pharma has cited Section 3(d) as a disincentive for Indian R&D; some argue it affects inbound biotech investment
The India Pharma 2026 dialogue acknowledged this tension: encouraging innovation while preserving affordability.
Global Context — The Pharma Chessboard
The “China+1” Opportunity
Post-COVID and amid US-China tensions, global pharma supply chains are diversifying away from pure China dependence. India is the natural beneficiary because:
- Large English-speaking STEM workforce
- Democratic governance (lower supply-chain political risk)
- Existing USFDA-approved manufacturing base
However, Vietnam, Indonesia, and increasingly Malaysia are competing for the same diversification dollars.
The US-India Pharma Relationship
- USA is India’s largest pharma export destination (~$9 billion, FY 2024-25)
- India supplies ~40% of all generic drugs consumed in the USA
- US pharma imports from India save American consumers an estimated $200+ billion annually
- Tensions: USTR Special 301 Report periodically flags India’s IP regime; some Big Pharma lobbies for weaker Section 3(d)
UPSC Relevance
| Paper | Angle |
|---|---|
| GS2 — IR | India-US pharma trade; global supply chain diversification; USTR Special 301 |
| GS3 — Economy | PLI schemes; CRDMO; biosimilar market; API self-sufficiency; trade deficit |
| GS3 — S&T | Drug discovery pipeline; biologics; mRNA platforms; CDSCO regulation |
| GS4 — Ethics | Patent vs public health tension; Section 3(d); affordable medicines vs innovation incentives |
| Prelims | India Pharma 2026 — 9th edition; Min: J.P. Nadda + Anupriya Patel; venue: FICCI New Delhi; India share of global generics: ~20%; FDA-approved sites: >650; PLI for Pharma: ₹15,000 cr; Section 3(d) — Novartis case (2013); Patents Act 1970 |
| Interview | “Has India’s generics model reached structural limits? What policy would push innovation without sacrificing affordability?” |
📌 Facts Corner
India Pharma 2026: Edition: 9th · Dates: April 13-14, 2026 · Venue: Federation House, FICCI, New Delhi · Theme: “Discover in India: Leapfrogging Life-Sciences Innovation” · Inaugurated by J.P. Nadda (Chem & Fert.) + Anupriya Patel · Organised by: Dept of Pharmaceuticals + FICCI.
India Pharma Sector: Domestic market: ~$55 billion · Exports: ~$27 billion (FY 2024-25) · Global generics share (volume): ~20% · Global vaccine share (volume): ~60% · USFDA-approved sites: >650 · 3rd by volume, 11th by value globally.
Key Schemes: PLI Pharma (2021): ₹15,000 cr · PLI Bulk Drugs (2020): ₹6,940 cr · PRIP (2023): ₹5,000 cr · Bulk Drug Parks: 3 (Gujarat, HP, AP) · API import dependence: ~70%; from China: ~68%.
Regulation: CDSCO under Drugs & Cosmetics Act 1940 · Section 3(d) Patents Act 1970 (anti-ever-greening) · Novartis v. UoI (2013) — SC upheld 3(d) · GS3: Economy + S&T; GS2: IR.
